| payload |
{"created_at":"2026-04-22T03:03:32.063 {"created_at":"2026-04-22T03:03:32.063787+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:5b1bc697aa6a4220","evidence_event_ids":["evt_fb6685f38e89"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166732.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166732.txt","company":"Solid Biosciences Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166732.txt","article_chars":2492,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_ae4c5ceb69cd3d55","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166732.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:28:28.397167+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166732.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166732.txt","source_event_id":"evt_fb6685f38e89","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"ba744858a5f36d1e","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-21","2026-01-29","2027 (anticipated first quarter)","2024-06-11","2017-05-24"],"entities":[{"asset_class":"equity","name":"Solid Biosciences Inc.","relevance":"high","symbol":"SLDB","type":"issuer"},{"asset_class":"person","name":"Kevin Tan","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"person","name":"Kimberly Cornwell","relevance":"medium","symbol":"","type":"attorney_in_fact"}],"event_type":"listing","information_gaps":["The filing text provided does not include the full Form 4 transaction table details (e.g., whether there were sales/purchases vs. only grant/vesting reporting), beyond the RSU/PSU description.","The provided excerpt does not specify the exact number of PSUs/RSUs tied to the second milestone or the exact number of shares that will vest; it only describes the structure (25% per milestone).","The signal indicates 'SLDB filed 4' but the excerpt does not explicitly state the ticker beyond 'SLDB' in the structured context; the excerpt itself does not show a ticker field."],"key_facts":["SEC filing is Form 4 (CONFORMED SUBMISSION TYPE: 4) for Solid Biosciences Inc.","Filing accession number: 0001193125-26-166732; filed as of date: 2026-04-21.","Conformed period of report: 2026-01-29.","Reporting owner: Kevin Tan (central index key 0001884056).","The filing references Restricted Stock Units (RSUs) where each RSU represents a contingent right to receive one share of the issuer\u2019s common stock.","The filing states Performance Stock Units (PSUs) were granted on June 11, 2024.","The PSUs provide for vesting of 25% of the target number of underlying RSUs upon achievement of each of four independent performance milestones.","The performance milestones are described as non-market and non-financial in nature.","The second performance milestone was determined by the Board to be met on January 29, 2026.","Shares related to the second performance milestone will vest subject to the grantee\u2019s continued service with the Company on the evaluation date, anticipated to occur in the first quarter of 2027.","Signature: /s/ Kimberly Cornwell as attorney-in-fact for Kevin Tan; dated 2026-04-21."],"numeric_claims":[{"label":"Conformed period of report","value":"2026-01-29"},{"label":"Filed as of date","value":"2026-04-21"},{"label":"PSUs grant date","value":"2024-06-11"},{"label":"Number of performance milestones","value":"4"},{"label":"Vesting per milestone (percent of target)","value":"25%"}],"primary_claim":"On the Form 4 filed 2026-04-21, reporting owner Kevin Tan\u2019s award includes PSUs where the second performance milestone was determined met on January 29, 2026, with related shares vesting subject to continued service and an evaluation date anticipated in Q1 2027.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Solid Biosciences Inc. filed a Form 4 on 2026-04-21 reporting transactions by reporting owner Kevin Tan related to restricted stock units (RSUs) and performance stock units (PSUs). The filing indicates PSUs tied to four non-market, non-financial performance milestones, with the second milestone determined met on 2026-01-29 and vesting expected in Q1 2027 subject to continued service.","topics":["SEC Form 4","equity compensation","RSUs","PSUs","performance milestones","vesting","insider reporting"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Solid Biosciences Inc. \u00b7 Filed 20260421","ticker":"SLDB","tickers":["SLDB"],"title":"SLDB filed 4","url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-166732.txt"}}... |